O0884
Monoclonal Anti-Oncostatin M antibody produced in mouse
clone 17001, purified immunoglobulin, lyophilized powder
Synonym(s):
Anti-OSM
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
17001, monoclonal
form
lyophilized powder
species reactivity
human
technique(s)
indirect ELISA: suitable
neutralization: suitable
western blot: suitable
isotype
IgG2a
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... OSM(5008)
General description
Oncostatin M (OSM) is a growth-regulating cytokine produced by the activated T lymphocytes and macrophages. It has a pivotal role in stimulating the production of IL-6 in cultured human endothelial cells. It also facilitates the LDL receptor expression and its uptake by hepatoma cells. Further, OSM can induce synovial fibroblast-like cells to produce urokinase type plasminogen activator. Monoclonal anti-Oncostatin M antibody can be used for neutralizing the biological activity of rhOSM on the human TF-1 cell line. Mouse anti-Oncostatin M antibody reacts specifically with recombinant human OSM. The product has shown no cross-reactivity with recombinant human IL-6, IL-11, CNTF, LIF and recombinant mouse OSM.
Specificity
The antibody neutralizes the biological activity of recombinant human OSM. Does not cross-react with recombinant human IL-6, IL-11, CNTF, LIF and recombinant mouse OSM.
Immunogen
recombinant human OSM expressed in Escherichia coli.
Application
Monoclonal anti-Oncostatin M antibody can be used in western blotting and capture ELISA.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline (PBS) with 5% trehalose.
Preparation Note
Purified using protein A.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
T J Brown et al.
Journal of immunology (Baltimore, Md. : 1950), 147(7), 2175-2180 (1991-10-01)
Endothelial cells produce immunomodulatory cytokines in response to soluble mediators of inflammatory/immune reactions. We have previously demonstrated that the leukocyte-derived cytokine, oncostatin M (Onco M) can alter endothelial cell morphology, regeneration, and fibrinolytic activity in vitro. Here we demonstrate that
R I Grove et al.
The Journal of biological chemistry, 266(27), 18194-18199 (1991-09-25)
Oncostatin M is a growth regulatory protein secreted by macrophages and activated T lymphocytes. In a hepatoma cell line (HepG2) the polypeptide very potently increased low density lipoprotein (LDL) uptake with an EC50 of 0.1-0.2 nM. The stimulation of LDL
Oncostatin M stimulates urokinase-type plasminogen activator activity in human synovial fibroblasts.
J A Hamilton et al.
Biochemical and biophysical research communications, 180(2), 652-659 (1991-10-31)
Cytokine regulation of synovial cell function has been considered to be involved in the pathogenesis of rheumatoid arthritis. Synoviocyte urokinase-type plasminogen activator (u-PA) expression may be relevant to the tissue remodelling, as well as to the cell migration and transformation
T Kitamura et al.
Journal of cellular physiology, 140(2), 323-334 (1989-08-01)
We have established a novel cell line, designated as TF-1, from a patient with erythroleukemia, which showed complete growth dependency on granulocyte-macrophage colony-stimulating factor (GM-CSF) or on interleukin-3 (IL-3) and carried a homogeneous chromosomal abnormality (54X). Erythropoietin (EPO) also sustained
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service